Investor Relations

Eton Pharmaceuticals, Inc. is a specialty pharmaceutical company focused on developing, acquiring, and commercializing innovative products utilizing the FDA's 505(b)(2) regulatory pathway.

Eton has a diversified pipeline of product candidates under development across various liquid dosage forms, including injectables, oral liquids, and ophthalmics.

Volume :

Data Provided by Refinitiv. Minimum 15 minutes delayed.

News Releases
Eton Pharmaceuticals to Report Second Quarter Financial Results on Wednesday, August 12, 2020
August 4, 2020
DEER PARK, Ill. , Aug. 04, 2020 (GLOBE NEWSWIRE) -- Eton Pharmaceuticals, Inc (Nasdaq: ETON), a specialty pharmaceutical company focused on developing and commercializing innovative drug products, today announced that it will report second quarter 2020 financial and operating results on Wednesday,
Read More
Eton Pharmaceuticals Submits New Drug Application to the FDA for Zonisamide Oral Suspension (ET-104)
July 30, 2020
- Application Submitted for the Treatment of Partial Seizures in Epilepsy Patients - Eton’s Patent-Pending Product Addresses Significant Unmet Need for a Liquid Formulation of Zonisamide - Application is Eton’s Sixth Drug Application Under FDA Review DEER PARK, Ill.
Read More
Eton Pharmaceuticals Submits New Drug Application to the FDA for Orphan Drug Dehydrated Alcohol Injection (DS-100)
July 27, 2020
-Granted Orphan Drug Designation by the FDA for the Treatment of Methanol Poisoning -Since the Start of COVID-19, the FDA has Recalled More Than 75 Contaminated Hand Sanitizers Due to Risk of Methanol Poisoning -DS-100 is Eton’s Fifth Drug Application Under FDA Review and Second Orphan Application
Read More
Email Alerts

Eton
Latest Event

Eton Pharma Reports Positive Top-Line Results from Phase III Trial of EM-100 Ophthalmic Solution